AN2 Therapeutics Income Statement (2021-2026) | ANTX

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
3.85M5.34M5.31M5.63M6.70M7.43M8.75M11.98M13.54M14.43M14.92M14.65M12.15M8.29M5.40M7.69M3.20M7.00M6.88M6.74M
Selling, General & Administrative (Quarter)
0.90M1.59M1.78M2.05M3.63M3.34M3.72M4.05M3.06M3.75M3.90M3.64M3.73M3.48M3.21M3.85M4.02M3.04M2.44M3.81M
Restructuring Costs (Quarter)
2.24M-0.01M
Other Operating Expenses (Quarter)
0.25M0.50M1.00M
Operating Expenses (Quarter)
5.00M6.93M7.59M7.68M10.33M11.77M12.48M16.04M16.60M18.18M18.82M18.30M15.88M14.01M8.60M11.54M7.22M10.04M9.32M10.55M
Operating Income (Quarter)
-5.00M-6.93M-7.59M-7.68M-10.33M-11.77M-12.48M-16.04M-16.60M-18.18M-18.82M-18.30M-15.88M-14.01M-8.60M-11.54M-7.22M-10.04M-9.32M-10.55M
EBIT (Quarter)
-5.00M-6.93M-7.59M-7.68M-10.33M-11.77M-12.48M-16.04M-16.60M-18.18M-18.82M-18.30M-15.88M-14.01M-8.60M-11.54M-7.22M-10.04M-9.32M-10.55M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.03M0.03M0.03M0.23M0.47M0.63M1.68M1.45M1.27M1.08M0.89M0.75M0.69M0.60M0.52M
Other Non Operating Income (Quarter)
-0.02M-0.04M0.02M0.03M0.21M0.43M0.63M0.72M0.80M1.47M-2.94M0.00M1.27M
Non Operating Income (Quarter)
-0.02M-0.04M0.02M0.03M0.21M0.43M0.63M0.72M0.80M1.47M-2.94M0.00M1.27M
Net income details
EBT (Quarter)
-4.98M-6.91M-7.57M-7.66M-10.11M-11.30M-11.85M-16.04M-16.60M-18.18M-18.82M-16.62M-14.44M-12.75M-7.52M-10.65M-6.46M-9.35M-8.71M-10.03M
Profit After Tax (Quarter)
-5.01M-6.94M-7.54M-7.66M-10.12M-11.34M-11.84M-15.32M-15.80M-16.71M-16.93M-16.62M-14.44M-12.75M-7.52M-10.65M-6.46M-9.35M-8.67M-10.03M
Income from Continuing Operations (Quarter)
-4.98M-6.91M-7.57M-7.66M-10.11M-11.30M-11.85M-16.04M-16.60M-18.18M-18.82M-16.62M-14.44M-12.75M-7.52M-10.65M-6.46M-9.35M-8.71M-10.03M
Consolidated Net Income (Quarter)
-4.98M-6.91M-7.57M-7.66M-10.11M-11.30M-11.85M-16.04M-16.60M-18.18M-18.82M-16.62M-14.44M-12.75M-7.52M-10.65M-6.46M-9.35M-8.71M-10.03M
Income towards Parent Company (Quarter)
-4.98M-6.91M-7.57M-7.66M-10.11M-11.30M-11.85M-16.04M-16.60M-18.18M-18.82M-16.62M-14.44M-12.75M-7.52M-10.65M-6.46M-9.35M-8.71M-10.03M
Preferred Dividend Payments (Quarter)
1.90M1.93M1.93M1.82M
Net Income towards Common Stockholders (Quarter)
-6.91M-8.87M-9.47M-9.47M-10.12M-11.34M-11.84M-15.32M-15.80M-16.71M-16.90M-16.62M-14.44M-12.75M-7.52M-10.65M-6.46M-9.35M-8.71M-10.03M
Additional items
EPS (Basic) (Quarter)
-2.62-3.35-3.58-2.98-0.53-0.59-0.58-0.79-0.81-0.65-0.52-0.56-0.48-0.43-0.25-0.35-0.21-0.31-0.28-0.29
EPS (Weighted Average and Diluted) (Quarter)
-2.62-3.35-3.58-2.98-0.53-0.59-0.58-0.79-0.81-0.65-0.52-0.56-0.48-0.43-0.25-0.35-0.21-0.31-0.28-0.29
Shares Outstanding (Weighted Average) (Quarter)
2.63M2.64M2.64M3.18M11.26M13.99M15.34M19.39M19.44M25.65M23.60M29.76M29.82M29.81M29.83M30.05M30.11M30.28M30.22M34.06M
Shares Outstanding (Diluted Average) (Quarter)
2.63M2.64M2.64M3.18M11.26M13.99M15.34M19.39M19.50M25.65M23.60M29.76M29.82M29.84M29.83M30.05M30.11M30.17M30.22M34.06M
EBITDA (Quarter)
-5.01M-6.95M-7.57M-7.79M-10.32M-11.52M-11.68M-15.12M-15.75M-16.71M-16.50M-16.84M-14.52M-12.61M-7.60M-10.63M-6.49M-9.31M-8.72M-10.09M
Shares Outstanding (Quarter)
2.73M2.73M2.73M18.71M19.40M19.40M19.40M19.43M21.93M29.74M29.74M29.82M29.83M29.87M29.92M30.14M27.38M27.37M27.41M35.99M